Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How Hospitals Can Adapt to Supply Chain Disruptions

COVID-19 has brought increasingly disruptive ripple effects across each of the world’s industries, but healthcare has been hit particularly hard. In addition to managing the increased stressors associated directly with the pandemic, healthcare providers the world over are dealing with the fallout of severe disruptions throughout their supply chains. In uncertain periods such as this,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
How Hospitals Can Adapt to Supply Chain Disruptions

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

COVID-19 has brought increasingly disruptive ripple effects across each of the world’s industries, but healthcare has been hit particularly hard.

In addition to managing the increased stressors associated directly with the pandemic, healthcare providers the world over are dealing with the fallout of severe disruptions throughout their supply chains.

In uncertain periods such as this, TPC stands ready to assist its Member hospitals in finding agile solutions to these disruptions that allow operations to remain as close to normal as possible as we collectively work through the challenges set in front of us.

As COVID-19 Proves, Healthcare Providers Must Be Ready to Pivot at a Moment’s Notice

Though COVID-19 is far from the first disruptive force healthcare supply chains have been asked to navigate, it has presented some unique challenges.

It’s more important than ever to evaluate best practices in adapting and responding to these disruptions.

First, it’s critical to thoroughly review not only your own supply chain, but the state of key drugs, other products, and their manufacturers. The FDA has been diligent in working with manufacturers of both drugs and medical equipment to get an idea of exactly how disruptive this pandemic might be, and it’s important that you leverage that information as often as you can to formulate a plan of attack that addresses potential impacts on your own supply chain.

Proactive risk management plans, data sharing and collaboration can ensure you’re firmly on the front line in fighting these disruptions and continuing to provide the key services and quality care for your patients.

Several best practices have also been recommended during this pandemic, including:

  • Providing education regarding COVID-19 to staff.
  • Rationing masks and personal protective equipment and curtailing areas where these products are available for use.
  • Managing N-95 mask usage and creating a proactive plan regarding nurses who will use the masks, careful attention to reuse guidelines, and more.

TPC is Proud to Help Guide You Through Uncertainty

As uncertainty mounts in the face of these supply chain disruptions, TPC is, as always, committed to acting as your guide toward proactive, beneficial action and working to source new suppliers and evaluate innovative solutions to assist our Members in their time of need.

With TPC’s ongoing commitment to communication and support, you can be confident in your ability to navigate these temporary disruptions and continue providing the best possible care to your patients.

Disruptions are going to occur, and COVID-19 is far from the last – however, by being flexible in addressing these challenges, we can work together to find solutions, providing valuable support within the TPC Member family.

To learn more or reach out with any specific questions, visit tpc1.com.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512